Key Highlights:
- Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, to commercialize two insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, in India.
- The partnership will strengthen Mankind Pharma’s diabetes care portfolio and expand its presence in the injectable diabetes segment by adding long-acting insulin and a combination insulin therapy. The agreement is also expected to provide patients in India with broader treatment options for diabetes management.
- The collaboration aligns with Mankind Pharma’s strategy of expanding its in-licensing pipeline through global partnerships, particularly with emerging biopharmaceutical companies in China. The company said it will continue to leverage China’s growing biopharmaceutical ecosystem to access differentiated assets and complement its existing portfolio.
Implications:
Mankind Pharma’s exclusive agreement with Chongqing Chenan adds two insulin analogues to its India portfolio, strengthening its position in the injectable diabetes segment and broadening its treatment offering beyond its existing insulin assets. The addition of Insulin Degludec and the Insulin Degludec + Aspart combination can help Mankind build a more comprehensive diabetes franchise while leveraging its established commercial presence in India. Strategically, the deal also highlights the company’s increasing focus on China as a source of differentiated biopharmaceutical assets, allowing it to expand its pipeline through in-licensing rather than relying solely on internal development. As Mankind continues to pursue similar partnerships, the approach could support faster portfolio expansion and improve access to advanced diabetes therapies in the Indian market.
Source: Express Pharma
